STOCK TITAN

Boston Scientific Corporation - BSX STOCK NEWS

Welcome to our dedicated page for Boston Scientific Corporation news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific Corporation stock.

Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.

The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.

Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.

Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.

Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.

On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.

Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.

As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.

Rhea-AI Summary

Boston Scientific (NYSE: BSX) reported strong Q2 2024 results, with net sales of $4.120 billion, up 14.5% on a reported basis and 14.7% organically. GAAP EPS was $0.22, while adjusted EPS reached $0.62, exceeding guidance. The company saw significant growth across segments, with Cardiovascular up 17.8% and MedSurg up 9.0%. Regionally, U.S. sales grew 16.9%, and Emerging Markets increased 14.8%. Key developments include NMPA approval in China for the FARAPULSE™ PFA System and positive clinical trial results for various products. Boston Scientific also announced plans to acquire Silk Road Medical. The company raised its full-year 2024 guidance, projecting net sales growth of 13.5-14.5% on a reported basis and adjusted EPS of $2.38-$2.42.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) announced it will hold a webcast to discuss its Q2 2024 financial results and business highlights on July 24, 2024, at 8:00 a.m. ET.

The call will be led by CEO Mike Mahoney and CFO Dan Brennan, with a news release detailing the financial results to be issued prior to the call. Investors can access the live webcast and a replay at the company's investor relations site starting one hour after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conference call earnings
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) has agreed to acquire Silk Road Medical (Nasdaq: SILK) for $27.50 per share, valuing the transaction at approximately $1.16 billion. The acquisition adds Silk Road's FDA-approved TCAR technology for stroke prevention to Boston Scientific's vascular portfolio. TCAR, a minimally invasive procedure, has shown reduced stroke risks and complications compared to traditional surgery. Silk Road Medical expects net revenue of $194-198 million in 2024, marking a 10-12% increase from the previous year. The transaction is set to close in the second half of 2024, with minimal impact on Boston Scientific's adjusted earnings per share in 2024 and 2025, and potential accretive effects thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
Rhea-AI Summary

Boston Scientific announced positive six-month results from the MODULAR ATP study of the mCRM System, which integrates the EMBLEM S-ICD and EMPOWER LP. The study met all safety and efficacy endpoints, showing a 97.5% major complication-free rate and a 98.8% communication success rate between devices. The ATP success rate was 61.3%, with no patients requesting therapy deactivation. The EMPOWER LP demonstrated stable device fixation. Findings were presented at Heart Rhythm 2024 and published in The New England Journal of Medicine. The APPRAISE ATP trial also supported the modular therapy approach, showing a small reduction in first all-cause shocks over five years in a large patient group. FDA approval is anticipated in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) has elected Dr. Cheryl Pegus to its board of directors, bringing over 25 years of clinical and business leadership experience to the company. Dr. Pegus has held various prominent positions in the healthcare industry, demonstrating a strong commitment to improving healthcare quality and accessibility. Her appointment is expected to enhance Boston Scientific's strategic growth and patient care initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
management
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) is set to participate in two upcoming investor conferences in May. The executives will engage in question-and-answer sessions at Bank of America's 2024 Health Care Conference on May 14 and at Bernstein's 40th Annual Strategic Decisions Conference on May 29. The webcasts and replays of both events will be accessible on the company's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
conferences
Rhea-AI Summary
Boston Scientific (NYSE: BSX) reported strong financial results for the first quarter of 2024, with net sales of $3.856 billion, a 13.8% increase on a reported basis. The company achieved GAAP net income of $495 million, compared to $300 million a year ago, and an adjusted EPS of $0.56. Various business segments and regions showed growth, with significant developments in product launches, clinical trials, and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Boston Scientific initiates NAVIGATE-PF study for FARAVIEW Software Module and FARAWAVE Nav Pulsed Field Ablation Catheter in atrial fibrillation treatment, aiming to improve patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Summary
Boston Scientific (BSX) will host a conference call on April 24, 2024, discussing financial results for the first quarter of 2024. The call, led by Mike Mahoney and Dan Brennan, will be followed by a news release. Investors can access the webcast on the company's investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
Rhea-AI Summary
Scivita Medical Technology Co., and Boston Scientific sign an expanded strategic cooperation agreement to introduce iterative endoscopic technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none

FAQ

What does Boston Scientific Corp. specialize in?

Boston Scientific specializes in developing, manufacturing, and marketing medical devices for interventional medical procedures, focusing on less invasive solutions.

What are the main segments of Boston Scientific?

The company operates through two main segments: MedSurg and Cardiovascular.

What recent financial achievement has Boston Scientific announced?

Boston Scientific recently completed a public offering of €2,000,000,000 in notes to finance the acquisition of Axonics, Inc. and to repay existing debt.

What is the AGENT™ Drug-Coated Balloon (DCB)?

The AGENT™ Drug-Coated Balloon is a novel device approved by the FDA to treat coronary in-stent restenosis in patients with coronary artery disease.

What is the focus of Boston Scientific’s latest clinical trials?

The NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System focus on improving patient outcomes and expanding product offerings.

How has Boston Scientific performed financially in 2024?

For the first quarter of 2024, Boston Scientific reported net sales of $3.856 billion, a 13.8% increase from the prior year.

What are some key products manufactured by Boston Scientific?

Boston Scientific manufactures products for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, and more.

How much of Boston Scientific’s sales come from international markets?

Nearly half of Boston Scientific's total sales are from international markets.

Who are Boston Scientific’s customers?

Boston Scientific markets its products to healthcare professionals and institutions globally.

What is Boston Scientific's vision for the future?

Boston Scientific aims to transform lives through innovative medical technologies that improve patient health and reduce healthcare costs.

Boston Scientific Corporation

NYSE:BSX

BSX Rankings

BSX Stock Data

115.72B
1.47B
0.19%
92.79%
0.78%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MARLBOROUGH